The Department of Veterans Affairs (VA) National Acquisition Center awarded an Indefinite Delivery Contract (IDC) to Xlcare Pharmaceuticals Inc., a minority-owned, small disadvantaged business, to provide Oxcarbazepine pharmaceutical products. The single-award IDC has a base period of performance from October 14, 2024 to October 13, 2025, with four one-year option periods, for a total potential contract value of $11,065,099.45. The contracted items will be distributed through the VA's and Department of Defense's (DOD) respective Pharmaceutical Prime Vendor Programs, and will also be available to the Bureau of Prisons (BOP) and Indian Health Service (IHS). The contract is unrestricted, with no set-aside designation. Offerors must provide the exact drug name, a unique NDC number, and all bottles of 100 tablets or less must have child-resistant closures. The estimated annual requirements include various Oxcarbazepine tablet sizes and quantities, but the actual award value or budget range is not specified. The NAICS code for this procurement is 325412 - Pharmaceutical Preparation Manufacturing.
The VA National Acquisition Center plans to issue a Request for Proposal (RFP) 36E79724R0021 for the procurement of Oxcarbazepine, with the solicitation expected to be electronically issued on or about July 1, 2024, and a tentative closing date of July 17, 2024. Interested offerors should continuously check the SAM.gov website for any amendments or updates to the solicitation.
Generated 8/16/24, 9:21 AM